Visoluten
Longevity & Cellular HealthAlso known as: Eye Bioregulator, Khavinson Eye Peptide, Visual Bioregulator, Retina Bioregulator Capsule
Mechanism
Visoluten is a peptide bioregulator designed to support eye health and visual function. It targets the retina and other ocular tissues, aiming to restore age-disrupted gene expression in photoreceptor cells, retinal pigment epithelium (RPE), and lens epithelium. Age-related vision loss — including macular degeneration, cataracts, and reduced night vision — stems partly from cumulative cellular damage. Visoluten works at the DNA level to help these delicate tissues maintain their specialized functions longer.
Technical detail
Visoluten is a short-chain peptide bioregulator from the Khavinson series targeting ocular tissues — primarily retinal pigment epithelium (RPE), photoreceptors (rods and cones), and lens epithelial cells. Proposed mechanism: nuclear DNA interaction in retinal cells to modulate expression of visual cycle enzymes (RPE65, LRAT), opsins (rhodopsin, cone opsins), and RPE-specific genes (BEST1, MERTK for photoreceptor outer segment phagocytosis). May support crystallin expression in lens epithelium for transparency maintenance. Potentially modulates VEGF/PEDF balance in RPE — relevant to age-related macular degeneration pathogenesis. Differs from Retinalamin (injectable retinal extract) by being an oral capsule formulation of synthetic peptides. Published data limited to Khavinson group.
Effects
OPHTHALMOLOGIC: Primary target system. Retinal and ocular tissues are among the most metabolically active and oxidatively stressed in the body — photoreceptors consume more oxygen per gram than any other tissue. Age-related ocular changes: (1) Retinal pigment epithelium (RPE) dysfunction — RPE supports photoreceptors by recycling visual pigments (visual cycle), phagocytosing shed photoreceptor outer segments, and maintaining the blood-retina barrier; RPE accumulates lipofuscin with age, leading to drusen formation and ultimately AMD; (2) Photoreceptor loss — rod and cone density declines with age, particularly in the macula; (3) Lens changes — crystallin protein cross-linking leads to yellowing and opacity (cataracts); (4) Decreased choroidal blood flow — reduces nutrient delivery to outer retina. Visoluten targets ocular tissue gene expression: RPE65 (retinol isomerase, essential for visual cycle), LRAT (lecithin:retinol acyltransferase), crystallin genes, bestrophin-1 (BEST1, chloride channel for RPE fluid transport), and MERTK (phagocytosis receptor for outer segment recycling). NEUROLOGICAL: The retina is technically part of the central nervous system — retinal ganglion cells are CNS neurons whose axons form the optic nerve. Supporting retinal neural health supports visual processing. IMMUNE: RPE-derived PEDF (pigment epithelium-derived factor) has anti-inflammatory and anti-angiogenic properties — maintains immune privilege of the eye. CARDIOVASCULAR: Retinal microvascular health mirrors systemic vascular health — retinal imaging is used as a window into cardiovascular disease. Tier 3: Users report improved night vision, reduced eye fatigue (especially from screen use), and stabilized visual acuity over time.
Practitioner Guide
DOSING TIPS: Standard protocol: 1-2 capsules daily for 10-30 days, repeated every 3-6 months. Take with a fat-containing meal (retinal-active nutrients are fat-soluble). SUPPLEMENT SYNERGIES: AREDS2 formulation (lutein 10mg, zeaxanthin 2mg, vitamin C 500mg, vitamin E 400IU, zinc 80mg, copper 2mg) — gold-standard evidence for AMD prevention and slowing. Astaxanthin (6-12mg/day) — potent antioxidant that crosses the blood-retina barrier; reduces eye fatigue. Bilberry extract (160-320mg/day standardized to 25% anthocyanins) — supports rhodopsin regeneration and night vision. Omega-3 DHA (1000mg+/day) — DHA constitutes 60% of photoreceptor outer segment membranes. Retinalamin (injectable) for more intensive retinal support — different formulation but same Khavinson lineage. CYCLING: Standard Khavinson protocol. CONTRAINDICATION NUANCES: Wet AMD requiring anti-VEGF injections — bioregulator is not a substitute for standard treatment. Retinal detachment — surgical emergency, not amenable to bioregulation. Diabetic retinopathy — manage blood sugar as primary intervention. STORAGE: Room temperature, protect from light. PATIENT EDUCATION: Your retina is the most metabolically active tissue in your body — more oxygen-hungry than your brain or heart muscle. Every day, your RPE cells recycle 10% of your photoreceptor cells. This incredible turnover makes the retina both vulnerable to aging and potentially responsive to bioregulation. Combine with AREDS2 vitamins, wear UV-blocking sunglasses, and take screen breaks (20-20-20 rule). Get annual dilated eye exams to track retinal health.
Research Summary
TIER 1 (Gold Standard): No Western clinical trials specific to Visoluten. AREDS and AREDS2 trials (NEI/NIH) provide gold-standard evidence for retinal nutrient supplementation (for context). TIER 2 (Strong): Khavinson bioregulation theory. Retinal biology and aging well-characterized (ARVO publications, ophthalmology textbooks). Related product Retinalamin has more published clinical data from Russia. TIER 3 (Moderate): Khavinson group ocular bioregulator publications. Retinalamin clinical data from Russian ophthalmology literature. Practitioner reports. KEY FINDINGS: (1) Retinal tissue is a compelling bioregulator target due to extreme metabolic demand and limited regenerative capacity. (2) Visoluten (oral) is less studied than Retinalamin (injectable). (3) No independent validation. GAPS: Standard Khavinson gaps. Oral bioavailability of eye-targeting peptides is particularly uncertain.